ArticleEJNMMI physics2026
Influence of increased injected activities up 9.0 GBq [
Article in EJNMMI physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAdministration activities of
methodsIn this single center, retrospective analysis, patients with PSMA-avid metastatic castration-resistant prostate cancer treated with [
results76 patients treated were included: 22 and 54 were injected with 9.1 ± 0.3 and 7.4 ± 0.3 GBq respectively. The AD/GBq to the kidney was comparable, 0.29 ± 0.08 vs. 0.33 ± 0.13 Gy/GBq [p=0.193] (9.1 vs. 7.4 GBq). The tumor AD/GBq was comparable between 9.1 and 7.4 GBq cohorts: total tumor burden (0.95 ± 0.42 vs. 0.92 ± 0.52 Gy/GBq) [p=0.302]; bone lesions 0.78 ± 0.42 vs. 0.74 ± 0.46 Gy/GBq [p=<0.001]; hottest lesion in each patient 1.37 ± 0.61 vs. 1.30 ± 0.74 [p=0.421]; coldest lesion in each patient 0.40 ± 0.16 vs. 0.50 ± 0.32 Gy/GBq [p=0.930].
conclusionThe AD/GBq across the disease burden, individual lesions, and kidney remained comparable even with increased injected activity. No evidence of the tumor sink effect was found. No evidence of a clinically relevant tumor sink effect in patients with <2000 mL tumor volume was found but patients with substantially high TTV (> 2 L) lacks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.